Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: An observational cohort study

Journal of Clinical Oncology

Volumn 32, Issue 31, 2014, Pages 3559-3567

  Ganz, Patricia A ^a,b   Petersen, Laura ^b   Castellon, Steven A ^c,d   Bower, Julienne E ^d,e   Silverman, Daniel H S ^b   Cole, Steven W ^b,e   Irwin, Michael R ^b,e   Belin, Thomas R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; COGNITIVE DEFECT; EARLY CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NEUROPSYCHOLOGICAL TEST; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; QUESTIONNAIRE; SELF REPORT; ADJUVANT CHEMOTHERAPY; AGED; BREAST NEOPLASMS; CANCER STAGING; COGNITION DISORDERS; COHORT ANALYSIS; MIDDLE AGED; PATHOLOGY; QUALITY OF LIFE; RISK FACTOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION DISORDERS; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEUROPSYCHOLOGICAL TESTS; QUALITY OF LIFE; RISK FACTORS; TAMOXIFEN;

EID: 84907250014     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.1662     Document Type: Article

References (48)

1. Ahles TA, Saykin AJ, McDonald BC, et al: Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: Impact of age and cognitive reserve. J Clin Oncol 28:4434-4440, 2010
2. Ahles TA: Brain vulnerability to chemotherapy toxicities. Psychooncology 21:1141-1148, 2012
3. Ahles TA, Root JC, Ryan EL: Cancer- and cancer treatment-associated cognitive change: An update on the state of the science. J Clin Oncol 30:3675-3686, 2012
4. Schagen SB, Vardy J, Steering Committee of the International Cognition and Cancer Task Force: Cognitive dysfunction in people with cancer. Lancet Oncol 8:852-853, 2007
5. Mandelblatt JS, Hurria A, McDonald BC, et al: Cognitive effects of cancer and its treatments at the intersection of aging: What do we know; what do we need to know? Semin Oncol 40:709-725, 2013
6. Castellon SA, Ganz PA, Bower JE, et al: Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26:955-969, 2004
7. van Dam FS, Schagen SB, Muller MJ, et al: Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210-218, 1998
8. Schagen SB, van Dam FS, Muller MJ, et al: Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640-650, 1999
9. Scherling C, Collins B, Mackenzie J, et al: Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: A functional magnetic resonance imaging study. J Clin Exp Neuropsychol 34:543-560, 2012
10. Ahles TA, Saykin AJ: Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7:192-201, 2007
11. Collins B, Mackenzie J, Stewart A, et al: Cognitive effects of hormonal therapy in early stage breast cancer patients: A prospective study. Psychooncology 18:811-821, 2009
12. Ganz PA, Kwan L, Castellon SA, et al: Cognitive complaints after breast cancer treatments: Examining the relationship with neuropsychological test performance. J Natl Cancer Inst 105:791-801, 2013
13. Bender CM, Sereika SM, Berga SL, et al: Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 15:422-430, 2006
14. Schilder CM, Seynaeve C, Beex LV, et al: Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: Results from the neuropsychological side study of the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol 28:1294-1300, 2010
15. Ganz PA, Bower JE, Kwan L, et al: Does tumor necrosis factor-alpha (TNFalpha) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun 30:S99-S108, 2013 (suppl)
16. Beck AT, Steer RA, Brown GK: Beck Depression Inventory Manual (2nd ed). Boston, MA, Harcourt Brace, 1996
17. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473-483, 1992
18. McHorney CA, Ware JE Jr, Raczek AE: The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247-263, 1993
19. Hays RD, Sherbourne CD, Mazel RM: The RAND 36-item health survey 1.0. Health Econ 2:217-227, 1993
20. Ware JE Jr, Kosinki M, Keller SD: SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA, The Health Institute, 1994
21. Chelune CJ, Heaton RK, Lehman RAW: Neuropsychological and personality correlates of patients' complaints of disability, in Goldstein G, Tarter RE (eds): Advances in Clinical Neuropsychology (vol 3). New York, NY, Plenum Press, 1986, pp 95-126
22. Pullens MJ, De Vries J, Roukema JA: Subjective cognitive dysfunction in breast cancer patients: A systematic review. Psychooncology 19:1127-1138, 2010
23. Bender CM, Pacella ML, Sereika SM, et al: What do perceived cognitive problems reflect? J Support Oncol 6:238-242, 2008
24. Collins B, Mackenzie J, Kyeremanteng C: Study of the cognitive effects of chemotherapy: Considerations in selection of a control group. J Clin Exp Neuropsychol 35:435-444, 2013
25. Tulsky DS, Price LR: The joint WAIS-III and WMS-III factor structure: Development and crossvalidation of a six-factor model of cognitive functioning. Psychological Assessment 15:149-162, 2003
26. Tombaugh TN, Kozak J, Rees L: Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol 14:167-177, 1999
27. Partridge AH, LaFountain A, Mayer E, et al: Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26:556-562, 2008
28. Partridge AH, Wang PS, Winer EP, et al: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602-606, 2003
29. Hershman DL, Kushi LH, Shao T, et al: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8, 769 early-stage breast cancer patients. J Clin Oncol 28:4120-4128, 2010
30. Hershman DL, Shao T, Kushi LH, et al: Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529-537, 2011
31. Ganz PA: "Doctor, will the treatment you are recommending cause chemobrain?" J Clin Oncol 30:229-231, 2012
32. Pomykala KL, de Ruiter MB, Deprez S, et al: Integrating imaging findings in evaluating the postchemotherapy brain. Brain Imaging Behav 7:436-452, 2013
33. Kampen DL, Sherwin BB: Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol 83:979-983, 1994
34. Carlson LE, Sherwin BB: Higher levels of plasma estradiol and testosterone in healthy elderly men compared with age-matched women may protect aspects of explicit memory. Menopause 7:168-177, 2000
35. Phillips SM, Sherwin BB: Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 17:485-495, 1992
36. Sherwin BB, Henry JF: Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: A critical review. Front Neuroendocrinol 29:88-113, 2008
37. Maki PM, Freeman EW, Greendale GA, et al: Summary of the National Institute on Agingsponsored conference on depressive symptoms and cognitive complaints in the menopausal transition. Menopause 17:815-822, 2010
38. Maki PM, Dennerstein L, Clark M, et al: Perimenopausal use of hormone therapy is associated with enhanced memory and hippocampal function later in life. Brain Res 1379:232-243, 2011
39. Maki PM, Rich JB, Rosenbaum RS: Implicit memory varies across the menstrual cycle: Estrogen effects in young women. Neuropsychologia 40:518-529, 2002
40. Buwalda B, Schagen SB: Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment? Life Sci 93:581-588, 2013
41. Jenkins V, Shilling V, Fallowfield L, et al: Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13:61-66, 2004
42. Jenkins V, Shilling V, Deutsch G, et al: A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828-834, 2006
43. Schilder CM, Eggens PC, Seynaeve C, et al: Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 48:76-85, 2009
44. Hurria A, Patel SK, Mortimer J, et al: The effect of aromatase inhibition on the cognitive function of older patients with breast cancer. Clin Breast Cancer 14:132-140, 2014
45. Jim HS, Phillips KM, Chait S, et al: Metaanalysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30:3578-3587, 2012
46. Pomykala KL, Ganz PA, Bower JE, et al: The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging Behav 7:1-13, 2013
47. Rugo HS, DeLuca AN, Heflin L, et al: Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (ESBC): Predictors of cognitive decline. J Clin Oncol 31:418s, 2013 (suppl 15; abstr 6620)
48. Rugo HS, Ahles T: The impact of adjuvant therapy for breast cancer on cognitive function: Current evidence and directions for research. Semin Oncol 30:749-762, 2003